Cancer-associated thrombosis is a condition where patients with active cancer have a higher risk of deep vein thrombosis and pulmonary embolism compared to the general population.1-2 Compared to patients without cancer-associated thrombosis, patients with cancer-associated thrombosis have a higher morbidity and mortality, higher likelihood of cancer progression, and increased health care costs.2-4 Specifically, patients with renal cell carcinoma have a higher risk of thromboembolism compared to other cancers, due to a higher risk of thromboembolism, both anatomically through direct invasion of the IVC, as well as biologically through overexpression of tissue factor on cancer cells and cancer cell microparticles.1,5